XFOR

X4 Pharmaceuticals, Inc.

A Boston-based biopharmaceutical company that makes medicines for rare immune-system diseases. Its drug XOLREMDI (mavorixafor), an oral pill approved by the FDA, treats WHIM syndrome, an ultra-rare inherited disorder that traps infection-fighting white blood cells in the bone marrow. Founded around 2015, the company took its name from the CXCR4 receptor its drug targets, and it built its lead medicine from a molecule originally developed by Sanofi.

Recent Activity

Show $

2019Q3

1 sell

First Eagle Investment ManagementEXIT

-35.7K shares

First Eagle Investment ManagementEXIT

-35.7K shares

2019Q2

1 buy

First Eagle Investment ManagementADD

+15.0K shares(+72.4%)

First Eagle Investment ManagementADD

+15.0K shares(+72.4%)

2019Q1

1 buy

First Eagle Investment ManagementNEW

+20.7K shares

First Eagle Investment ManagementNEW

+20.7K shares